Floatz logo

Busulphan

Common Variable Immunodeficiency

Masonic Cancer Center, University of MinnesotaN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Common Variable Immunodeficiency cohort.

Asset / SponsorPhaseRating
Conestat Alfa
IMMUNOe Research Centers
Phase 4BB
Thiotepa
University of Florida
Phase 2BB
HUMAN IMMUNOGLOBULINS
Grifols Therapeutics LLC
Phase 3B
Evomela
Paul Szabolcs
Phase 2CCC
Fludarabine
Paul Szabolcs
Phase 2CCC

View all 19 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →